drugset / Trial / NCT01024244

A Study of LY2599506 in Patients With Type 2 Diabetes

NCT01024244

Phase 2 Terminated 78 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to help answer the following questions: * To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. * To evaluate the safety of LY2599506 in participants with diabetes. * To determine if LY2599506 has the ability to control blood sugar in participants with diabetes. * To determine how much LY2599506 should be given to participants. * To determine if LY2599506 has an effect on a participant's weight. The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.

Timeline

Start
2009-12
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2599506 Unknown 100 mg Oral
Subject LY2599506 Unknown 200 mg Oral
Subject LY2599506 Unknown 400 mg Oral